Himanshu Rai

About

Himanshu Rai graduated from Gautam Buddha Technical University (U.P, India) in 2011 with a bachelor's degree in pharmacy. He finished his Master's degree in Pharmaceutical Chemistry in 2013 from the Bharti Vidyapeeth Deemed University (Maharashtra, India). From 2013 until 2019, he worked as a Medicinal Chemist (Research Scientist) in Mankind Pharma, Gurugram, India. In 2019, he joined as ICMR Project Fellow in the Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology, Banaras Hindu University (U.P, India) for Ph.D. program in the laboratory of Dr. Gyan Prakash Modi. His current research interests focus on structure-based design and development of new NIRF probes targeting marker proteins of Alzheimer's Disease.

Employment

Employment history is unavailable.

Education

• Indian Institute of Technology BHU Doctor of Philosophy
  2020 - 2026
• Bharati Vidyapeeth (Deemed to be University) Poona College of Pharmacy master in pharmacy
  2011 - 2013

Projects & Funding

Projects & funding information is unavailable.

Publications (8)

• Discovery of NIRF theranostic probes targeting amyloid-β and cholinesterases in Alzheimer’s disease models
  Nature Communications 2026 DOI: 10.1038/s41467-025-68282-3
  +Save
• New D‐π‐A‐Based Coumarin‐ Derived Fluorescent Theranostic Probes With Broad‐Spectrum Antimicrobial Activity
  Archiv der Pharmazie 2025 DOI: 10.1002/ardp.70032
  +Save
• Rhodanine composite fluorescence probes to detect amyloid-beta aggregated species in Alzheimer's disease models
  2023 DOI: 10.21203/rs.3.rs-2721179/v1
  +Save
• Near-Infrared Fluorescent Probes as Imaging and Theranostic Modalities for Amyloid-Beta and Tau Aggregates in Alzheimer’s Disease
  Journal of Medicinal Chemistry 2022 DOI: 10.1021/acs.jmedchem.1c01619
  +Save
• Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19
  Molecular Diversity 2021 DOI: 10.1007/s11030-021-10188-5
  +Save
• A review on ferulic acid and analogs based scaffolds for the management of Alzheimer’s disease
  European Journal of Medicinal Chemistry 2021 DOI: 10.1016/j.ejmech.2021.113278
  +Save
• Amide-linked Ethanolamine Conjugate of Gemfibrozil as a Profound HDL Enhancer: Design, Synthesis, Pharmacological Screening and Docking Study
  Current Drug Discovery Technologies 2015 DOI: 10.2174/1570163812666150819095640
  +Save
• Design and Development of Novel Azo Prodrugs using Various Permutations and Combinations of 5- and 4-Aminosalicylic Acids for Inflammatory Bowel Disease: A Colon-Targeted Approach
  Inflammation & Allergy-Drug Targets 2013 DOI: 10.2174/18715281113129990059
  +Save